Movement Disorders Clinical Practice最新文献

{"title":"AFF2 Repeat Expansion as a Fragile X-Associated Tremor/Ataxia Syndrome Mimic: Expanding the Phenotypic Spectrum of Fragile XE Syndrome.","authors":"Jacky Ganguly, Francesca Magrinelli, Antonio Funcis, Wai Kit Wong, Elena Ardila Jurado, Anna Latorre, Kailash Bhatia","doi":"10.1002/mdc3.70853","DOIUrl":"10.1002/mdc3.70853","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Patient Reported Change Guide Clinical Decisions after Unilateral Deep Brain Stimulation?","authors":"Jing Huang, Yuerong Ma","doi":"10.1002/mdc3.70850","DOIUrl":"10.1002/mdc3.70850","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Influence of Symptoms and Psychosocial Factors on Quality of Life and Life Satisfaction in Parkinson's Disease.","authors":"Francesca Gaiera, Emma O'Shea, Gerard W O'Keeffe, Zahra Azizi, Suzanne Timmons","doi":"10.1002/mdc3.70834","DOIUrl":"10.1002/mdc3.70834","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) symptoms affects quality of life (QoL), but effects on life satisfaction (LS) are less studied.</p><p><strong>Objectives: </strong>This study explored influences of motor and non-motor symptoms on QoL and LS in people with PD in Ireland.</p><p><strong>Methods: </strong>Eight hundred twenty nine people with PD completed a survey of validated tools, exploring motor and non-motor symptoms, social connectedness, self-efficacy, and stigma, and QoL and LS. Linear and multiple regression analyses assessed influences on QoL and LS.</p><p><strong>Results: </strong>Stigma and low self-efficacy were associated with poor QoL and LS; low social connectedness, dexterity issues, anxiety and apathy were associated with poor LS. Higher symptom burden, particularly dexterity, tremor, bradykinesia, freezing, cognition, psychosis, apathy, daytime sleepiness and urinary problems were associated with low QoL, but less than stigma.</p><p><strong>Conclusion: </strong>Policies to improve QoL and LS should target stigma and low self-efficacy.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microelectrode Recording in DBS Surgery: An Educational Resource.","authors":"Wander Leão Valentim, Corneliu Luca, Jason Margolesky, Todd M Herrington","doi":"10.1002/mdc3.70820","DOIUrl":"10.1002/mdc3.70820","url":null,"abstract":"<p><p>Microelectrode recording (MER) is a technique used during deep brain stimulation (DBS) surgery to guide electrode placement. After a stereotactic trajectory has been planned based on pre- and intraoperative imaging, a microelectrode capable of recording extracellular action potentials is inserted along the planned DBS electrode trajectory. By recognizing the characteristic features of the target structures, the intraoperative neurophysiologist and neurosurgeon work together to confirm that the trajectory is appropriate.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of the Felix NeuroAI Wristband for Essential Tremor: Results of a 1-Year Open-Label Extension Trial.","authors":"Stuart H Isaacson, Yongsheng Hu, William G Ondo, Wen Lv, Xiaodong Zhu, Yuan Yuan, Alberto J Espay, David Kreitzman, Sheng-Han Kuo, Salima Brillman, Holly A Shill, Kelly E Lyons, Zhi Yang, Qi Zhao, Zhen Zhang, Rajesh Pahwa","doi":"10.1002/mdc3.70833","DOIUrl":"https://doi.org/10.1002/mdc3.70833","url":null,"abstract":"<p><strong>Background: </strong>Essential tremor (ET) impacts daily activities and quality of life. A pivotal study of a transcutaneous peripheral nerve stimulation (TPNS) device, the Felix NeuroAI Wristband, led to Food and Drug Administration (FDA) clearance in 2025.</p><p><strong>Objective: </strong>The aim of the study was to report 1-year follow-up results.</p><p><strong>Methods: </strong>Patients who completed the 90-day randomized phase could continue until 1 year after the baseline visit; those in the sham group were crossed over to active TPNS treatment (delayed-start TPNS). Outcome measures were assessed at 180 days and 1 year: modified Activities of Daily Living (mADL) subscale of TETRAS, Clinical and Patient Global Impression of Improvement (CGI-I and PGI-I), Quality of Life in Essential Tremor Questionnaire, and adverse device effects (ADEs).</p><p><strong>Results: </strong>Of 93 patients who entered the extension phase (58 TPNS and 35 delayed start), 57 (38 and 19, respectively) completed 1 year of follow-up. In the TPNS group, mADL improvement increased from 6.9 points at day 90 to 9.7 points at 1 year. Ninety days of active treatment improved mADL scores by 5.5 points in the delayed-start TPNS group (day 180). From baseline, TETRAS ADL scores in the TPNS group improved by 6.1 ± 6.0 points at 90 days and 9.3 ± 6.0 points at 1 year. CGI-I, PGI-I, and quality of life improved in both groups from 90 days to 1 year. Twenty-three new ADEs occurred (mild skin irritation, n = 22; muscle spasms, n = 1).</p><p><strong>Conclusions: </strong>TPNS use was associated with sustained functional improvement for up to 1 year with acceptable safety. Patients who initiated active therapy earlier demonstrated greater cumulative benefit.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13637423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parkinsonism and Cortical Myoclonus Due to Cryptococcal Encephalitis.","authors":"Benedetta Angeloni, Paula Gosse, Marcus Callister, Christos Ganos","doi":"10.1002/mdc3.70859","DOIUrl":"10.1002/mdc3.70859","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining the Clinical Phenotypic Ground Truth: Expert Interrater Agreement in Hyperkinetic Movement Disorders.","authors":"Madelein van der Stouwe, Olof Vermeulen, Wieke Eggink, Tove Henriksen, Eavan McGovern, Marenka Smit, Selma Aybek, Agnita Boon, Rick Brandsma, Andres Deik, Roberto Erro, Alberto Espay, Cristian Falup-Pecurariu, Stephen Frucht, Christos Ganos, Emilia Gatto, Rick Helmich, Christine Klein, Hans Koelman, Vincent Odekerken, Lisette Koens, Abhimanyu Mahajan, Francesca Morgante, Alexander Münchau, Pattamon Panyakaew, Kathryn Peall, Bélen Pérez-Dueñas, Emanuel Roze, Anna Sadnicka, Susanne Schneider, Petra Schwingenschuh, Tereza Serranova, Matej Skorvanek, Maria Stamelou, Gertrúd Tamas, Michele Tinazzi, Anna Valadas, Wim Vandenberghe, Jeroen de Vries, Rodi Zutt, Sterre van der Veen, Rogier Luiken, Inge Tuitert, Marina Tijssen","doi":"10.1002/mdc3.70808","DOIUrl":"https://doi.org/10.1002/mdc3.70808","url":null,"abstract":"<p><strong>Background: </strong>Reliable clinical phenotyping is crucial for diagnosis, treatment, and research in hyperkinetic movement disorders, yet its interrater reliability remains uncertain.</p><p><strong>Objectives: </strong>To quantify interrater agreement in clinical phenotyping of hyperkinetic movement disorders among experts in a large, phenotypically diverse cohort.</p><p><strong>Methods: </strong>Within the NEMO project, 161 patients with hyperkinetic movement disorders underwent standardized video assessments. Each patient was independently classified by three international movement disorders experts in a structured, stepwise procedure. Experts first assessed videos alone, then received clinical history and examination, and finally diagnostic test results. At each step, they assigned primary and secondary phenotypes and rated their diagnostic confidence. Interrater agreement was assessed using Fleiss' and Cohen's kappa.</p><p><strong>Results: </strong>Across all phenotypes, interrater agreement on the primary phenotype increased with added information (κ = 0.457 to κ = 0.607). Agreement with the NEMO reference classification similarly improved (κ = 0.478 to κ = 0.656). Among patients with a single dominant phenotype, agreement reached κ = 0.78. In 93% of cases, at least two out of three experts reached consensus. Agreement was substantially lower in patients with mixed or complex presentations, such as myoclonus-dystonia and functional movement disorders. Diagnostic certainty rose throughout, though secondary phenotype agreement remained poor. Experts rarely revised initial impressions, suggesting robust pattern recognition but also potential confirmation bias.</p><p><strong>Conclusions: </strong>Movement disorders specialists can reliably identify hyperkinetic phenotypes, even without in-person assessment. While complex, mixed and functional presentations remain diagnostically challenging, our findings reinforce the value of expert phenotyping in clinical care, training, and research, and provide a benchmark for future studies and computational approaches.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13636365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.","authors":"Kristi Meksi, Clara Simonetta, Valerio Ferrari, Giovanni Minutilli, Matteo Conti, Francesca Avvento, Tommaso Schirinzi, Diego Centonze, Alessandro Stefani, Mariangela Pierantozzi","doi":"10.1002/mdc3.70849","DOIUrl":"https://doi.org/10.1002/mdc3.70849","url":null,"abstract":"<p><strong>Background: </strong>Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD-related pain; however, its effects on different pain manifestations remain unclear.</p><p><strong>Objective: </strong>The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion.</p><p><strong>Methods: </strong>Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations.</p><p><strong>Results: </strong>At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged.</p><p><strong>Conclusions: </strong>LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deconstructing Ataxia with Oculomotor Apraxia: Toward a Gene-Based Classification and a Reappraisal of the Oculomotor Phenotype.","authors":"Luiz Eduardo Novis, Flávio Moura Rezende Filho, Anna Maria Gomes, Victor Rebelo Procaci, Orlando Graziani Povoas Barsottini, José Luiz Pedroso","doi":"10.1002/mdc3.70846","DOIUrl":"https://doi.org/10.1002/mdc3.70846","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III cannot Be Reliably Reduced for Predicting Time to Initiation of Parkinsonian Medication in Early Parkinson's Disease: An Item-Level Sensitivity Analysis.","authors":"Mohammad Samsul Alam, Glenn T Stebbins, Tiago A Mestre, Christopher G Goetz, Sheng Luo","doi":"10.1002/mdc3.70843","DOIUrl":"https://doi.org/10.1002/mdc3.70843","url":null,"abstract":"<p><strong>Background: </strong>The sum of clinician-rated MDS-UPDRS Part III Motor Examination items is widely used in Parkinson's disease (PD), but item- or subset prognostic value remains unclear. Whereas reduced subsets of patient-reported Parts IB + II show improved utility for predicting time to PD medication initiation, the validity of similar Part III subsets is unknown.</p><p><strong>Objectives: </strong>Determine whether a subset of MDS-UPDRS Part III items is superior in prognostic value to the full scale for time to PD medication initiation in early disease.</p><p><strong>Methods: </strong>Harmonized longitudinal data from six early PD cohorts, with time to PD medication initiation as the primary outcome, were analyzed using a longitudinal item response theory model to rank items, combining discrimination and information. Rank-driven cumulative subsets were formed to analyze the primary outcome using time-varying Cox models under clinically relevant follow-up windows. Subset performance was assessed using the C-index and compared with the full-item model using Wald tests. Successful item reduction required stable, significant improvement across all follow-up windows.</p><p><strong>Results: </strong>No item subset met the predefined criteria for stable and superior prognostic performance relative to the full Part III scale. Best reduced-subset versus full-model C-indices were similar and non-significant: 0.582 versus 0.581 under full follow-up, 0.602 versus 0.602 at 1 year, and 0.586 versus 0.585 at 2 years.</p><p><strong>Conclusions: </strong>Unlike Parts IB and II, no sensitivity-driven reduced subset significantly and consistently outperformed the full MDS-UPDRS Part III in predicting time to PD medication initiation in early PD, not supporting a reduction of the 33-item scale in this setting.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149112493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}